DSpace DSpace Softwareについて

01 奈良県立医科大学 >
011 医学部 >
0112 紀要 >
01121 Journal of Nara Medical Association >
Vol.67 No.1,2,3 >

このアイテムの引用には次の識別子を使用してください: http://hdl.handle.net/10564/3301

タイトル: コハク酸シベンゾリンにより遷延する低血糖症を来した維持透析患者の一例
その他のタイトル: A Case of Prolonged Hypoglycemia Induced by Cibenzollne Succinate in a Hemodialysis Patient.
著者: 上原, 彰允
菅生, 裕輝
横内, 剛
立石, 恵実
中川, 陽子
石神, 賢一
神古, 智子
杉本, 雅史
濱野, 一將
キーワード: Cibenzoline
to be taken as needed, Hypoglycemia, drug induced
Atrial Fibrilation
Renal dysfunction
発行日: 2016年6月30日
出版者: 奈良医学会
引用: Journal of Nara Medical Association Vol.67 No.1,2,3 p.35-40 (2016.06)
抄録: Cibenzoline succinate (Cibenzoline, CZ) may cause hypoglycemia as a side effect. Because CZ is mainly excreted by kidney, it is contraindicated in patients who are on hemodialysis. We experienced a case of prolonged hypoglycemia induced by CZ in a dialysis patient. He was prescribed CZ as medication to be taken as needed for palpitations related to atrial fibrillation attacks. Approximately 9 months later, he was brought to our hospital by ambulance due to chest oppression and general fatigue. He developed hypoglycemic coma on the third hospital day. The high serum concentration of immunoreactive insulin and serum C-peptide immunoreactivity suggested enhanced insulin secretion. The toxic plasma concentration of CZ (2,140 ng/ml) indicated that his hypoglycemic coma was induced by CZ. He needed intravenous hypertonic glucose injection for about 20 days to prevent the recurrence of hypoglycemia. The hypoglycemia induced by CZ may be prolonged over a few weeks in patients with reduced renal function, including patients on hemodialysis.
URI: http://hdl.handle.net/10564/3301
ISSN: 13450069
出現コレクション:Vol.67 No.1,2,3


ファイル 記述 サイズフォーマット
35-40p.コハク酸シベンゾリンにより遷延する低血糖症を来した維持透析患者の一例.pdf7.56 MBAdobe PDF見る/開く



Valid XHTML 1.0! Powered by DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - ご意見をお寄せください